These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 28163793)

  • 1. UroMark-a urinary biomarker assay for the detection of bladder cancer.
    Feber A; Dhami P; Dong L; de Winter P; Tan WS; Martínez-Fernández M; Paul DS; Hynes-Allen A; Rezaee S; Gurung P; Rodney S; Mehmood A; Villacampa F; de la Rosa F; Jameson C; Cheng KK; Zeegers MP; Bryan RT; James ND; Paramio JM; Freeman A; Beck S; Kelly JD
    Clin Epigenetics; 2017; 9():8. PubMed ID: 28163793
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urine cell-based DNA methylation classifier for monitoring bladder cancer.
    van der Heijden AG; Mengual L; Ingelmo-Torres M; Lozano JJ; van Rijt-van de Westerlo CCM; Baixauli M; Geavlete B; Moldoveanud C; Ene C; Dinney CP; Czerniak B; Schalken JA; Kiemeney LALM; Ribal MJ; Witjes JA; Alcaraz A
    Clin Epigenetics; 2018; 10():71. PubMed ID: 29854012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A noninvasive urine-based methylation biomarker panel to detect bladder cancer and discriminate cancer grade.
    Hermanns T; Savio AJ; Olkhov-Mitsel E; Mari A; Wettstein MS; Saba K; Bhindi B; Kuk C; Poyet C; Wild PJ; Noon A; Bashir S; Juvet T; Rendon RA; Waltregny D; van der Kwast T; Finelli A; Kulkarni GS; Fleshner NE; Lo K; Bapat B; Zlotta AR
    Urol Oncol; 2020 Jun; 38(6):603.e1-603.e7. PubMed ID: 32081560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A urine-based DNA methylation assay to facilitate early detection and risk stratification of bladder cancer.
    Ruan W; Chen X; Huang M; Wang H; Chen J; Liang Z; Zhang J; Yu Y; Chen S; Xu S; Hu T; Li X; Guo Y; Jiang Z; Chen Z; Huang J; Lin T; Fan JB
    Clin Epigenetics; 2021 Apr; 13(1):91. PubMed ID: 33902700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical evaluation of Bladder CARE, a new epigenetic test for bladder cancer detection in urine samples.
    Piatti P; Chew YC; Suwoto M; Yamada T; Jara B; Jia XY; Guo W; Ghodoussipour S; Daneshmand S; Ahmadi H; Rice J; Bhasin J; Holloway F; Tsai Y; Chihara Y; Liang G
    Clin Epigenetics; 2021 Apr; 13(1):84. PubMed ID: 33882992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DETECT I & DETECT II: a study protocol for a prospective multicentre observational study to validate the UroMark assay for the detection of bladder cancer from urinary cells.
    Tan WS; Feber A; Dong L; Sarpong R; Rezaee S; Rodney S; Khetrapal P; de Winter P; Ocampo F; Jalil R; Williams NR; Brew-Graves C; Kelly JD
    BMC Cancer; 2017 Nov; 17(1):767. PubMed ID: 29141603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MALBAC-based chromosomal imbalance analysis: a novel technique enabling effective non-invasive diagnosis and monitoring of bladder cancer.
    Liu H; He W; Wang B; Xu K; Han J; Zheng J; Ren J; Shao L; Bo S; Lu S; Lin T; Huang J
    BMC Cancer; 2018 Jun; 18(1):659. PubMed ID: 29907142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HOXA9, PCDH17, POU4F2, and ONECUT2 as a Urinary Biomarker Combination for the Detection of Bladder Cancer in Chinese Patients with Hematuria.
    Wu Y; Jiang G; Zhang N; Liu S; Lin X; Perschon C; Zheng SL; Ding Q; Wang X; Na R; Sun J; Xu J
    Eur Urol Focus; 2020 Mar; 6(2):284-291. PubMed ID: 30309818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methylomics analysis identifies ZNF671 as an epigenetically repressed novel tumor suppressor and a potential non-invasive biomarker for the detection of urothelial carcinoma.
    Yeh CM; Chen PC; Hsieh HY; Jou YC; Lin CT; Tsai MH; Huang WY; Wang YT; Lin RI; Chen SS; Tung CL; Wu SF; Chang DC; Shen CH; Hsu CD; Chan MW
    Oncotarget; 2015 Oct; 6(30):29555-72. PubMed ID: 26320192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Urine DNA methylation assay enables early detection and recurrence monitoring for bladder cancer.
    Chen X; Zhang J; Ruan W; Huang M; Wang C; Wang H; Jiang Z; Wang S; Liu Z; Liu C; Tan W; Yang J; Chen J; Chen Z; Li X; Zhang X; Xu P; Chen L; Xie R; Zhou Q; Xu S; Irwin DL; Fan JB; Huang J; Lin T
    J Clin Invest; 2020 Dec; 130(12):6278-6289. PubMed ID: 32817589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of bladder cancer in urine sediments by a hypermethylation panel of selected tumor suppressor genes.
    Pietrusiński M; Kȩpczyński Ƚ; Jȩdrzejczyk A; Borkowska E; Traczyk-Borszyńska M; Constantinou M; Kaƚużewski B; Borowiec M
    Cancer Biomark; 2017; 18(1):47-59. PubMed ID: 27814275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinct DNA methylation epigenotypes in bladder cancer from different Chinese sub-populations and its implication in cancer detection using voided urine.
    Chen PC; Tsai MH; Yip SK; Jou YC; Ng CF; Chen Y; Wang X; Huang W; Tung CL; Chen GC; Huang MM; Tong JH; Song EJ; Chang DC; Hsu CD; To KF; Shen CH; Chan MW
    BMC Med Genomics; 2011 May; 4():45. PubMed ID: 21599969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic markers of urothelial cancer based on DNA methylation analysis.
    Chihara Y; Kanai Y; Fujimoto H; Sugano K; Kawashima K; Liang G; Jones PA; Fujimoto K; Kuniyasu H; Hirao Y
    BMC Cancer; 2013 Jun; 13():275. PubMed ID: 23735005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of TERT promoter mutations in urinary cell-free DNA and sediment DNA for detection of bladder cancer.
    Stasik S; Salomo K; Heberling U; Froehner M; Sommer U; Baretton GB; Ehninger G; Wirth MP; Thiede C; Fuessel S
    Clin Biochem; 2019 Feb; 64():60-63. PubMed ID: 30528938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A methylation assay for the detection of non-muscle-invasive bladder cancer (NMIBC) recurrences in voided urine.
    Zuiverloon TC; Beukers W; van der Keur KA; Munoz JR; Bangma CH; Lingsma HF; Eijkemans MJ; Schouten JP; Zwarthoff EC
    BJU Int; 2012 Mar; 109(6):941-8. PubMed ID: 21756281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrative functional genetic-epigenetic approach for selecting genes as urine biomarkers for bladder cancer diagnosis.
    Eissa S; Matboli M; Essawy NO; Kotb YM
    Tumour Biol; 2015 Dec; 36(12):9545-52. PubMed ID: 26138586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urinary TERT promoter mutations are detectable up to 10 years prior to clinical diagnosis of bladder cancer: Evidence from the Golestan Cohort Study.
    Hosen MI; Sheikh M; Zvereva M; Scelo G; Forey N; Durand G; Voegele C; Poustchi H; Khoshnia M; Roshandel G; Sotoudeh M; Nikmanesh A; Etemadi A; Avogbe PH; Chopard P; Delhomme TM; Foll M; Manel A; Vian E; Weiderpass E; Kamangar F; Boffetta P; Pharaoh PD; Dawsey SM; Abnet CC; Brennan P; McKay J; Malekzadeh R; Calvez-Kelm FL
    EBioMedicine; 2020 Mar; 53():102643. PubMed ID: 32081602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of bladder cancer using novel DNA methylation biomarkers in urine sediments.
    Chung W; Bondaruk J; Jelinek J; Lotan Y; Liang S; Czerniak B; Issa JP
    Cancer Epidemiol Biomarkers Prev; 2011 Jul; 20(7):1483-91. PubMed ID: 21586619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Highly Sensitive and Specific Detection of Bladder Cancer via Targeted Ultra-deep Sequencing of Urinary DNA.
    Ward DG; Baxter L; Ott S; Gordon NS; Wang J; Patel P; Piechocki K; Silcock L; Sale C; Zeegers MP; Cheng KK; James ND; Bryan RT;
    Eur Urol Oncol; 2023 Feb; 6(1):67-75. PubMed ID: 35410825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Promoter hypermethylation of HS3ST2, SEPTIN9 and SLIT2 combined with FGFR3 mutations as a sensitive/specific urinary assay for diagnosis and surveillance in patients with low or high-risk non-muscle-invasive bladder cancer.
    Roperch JP; Grandchamp B; Desgrandchamps F; Mongiat-Artus P; Ravery V; Ouzaid I; Roupret M; Phe V; Ciofu C; Tubach F; Cussenot O; Incitti R
    BMC Cancer; 2016 Sep; 16(1):704. PubMed ID: 27586786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.